Glaucoma Clinical Trial
Official title:
Prospective Case-controlled Study Comparing 5-Fluorouracil vs 5-Fluorouracil With Viscoelastic (Hyaluronic Acid) Formulation for the Prevention of Subconjunctival Scarring Post-trabeculectomy
Trabeculectomy is the most effective method of lowering intraocular pressure in glaucoma
that is not well controlled with drop medication. The post-operative wound healing response
remains the major barrier in surgical success. Scar tissue formation results in occlusion of
the surgical drainage site created. As a consequence, the intraocular pressure rises once
again. The current use of anti-scarring agents such as 5 Fluorouracil (5FU), is a well
established method employed by ophthalmologists to clinically reduce the postoperative
scarring response. However, in patients with a high risk of bleb failure, repeated
subconjunctival injections of 5FU following bleb needling is often required resulting in
increased clinical load and patient inconvenience. A slow release formulation of 5FU would
be of benefit by releasing the 5FU into the subconjunctival space over an extended period
thereby providing a prolonged therapeutic effect. In addition, hyaluronic acid is known to
possess antifibrotic properties and from its gel-like physical state, would potentially act
as a physical tissue spacer that may further limit active subconjunctival scarring at the
site where it is injected. We hypothesise that injecting a mixture of 5FU with hyaluronic
acid would give better outcomes than injecting 5FU alone.
The aim of this study is to determine whether bleb needling with subconjunctival injection
of Viscoelastic/5FU formulation is an effective method for prolonged drug delivery in
preventing the post-operative scarring response. This will be a prospective case-controlled
study involving patients who have already undergone trabeculectomy and who require bleb
needling and subconjunctival 5FU injections.
Specific Aims
The aim of this study is to determine whether needling of the conjunctival bleb after
trabeculectomy with subconjunctival injection of a 5 Fluorouracil (5FU)/ viscoelastic
formulation is an effective method for prolonged drug delivery in preventing post-operative
scarring in the conjunctiva.
Study Design
Cell Culture Experiments
Cell culture experiments were carried out to determine the effect of the hyaluronic acid, at
varying commercially available concentrations, on human Tenon's fibroblasts, the target cell
type of our proposed HA/ 5FU mixture. We also perform tests to examine the pharmacokinetic
drug release profiles of the different 5FU/HA formulations. This allowed us to determine the
most effective formulation to use for patients in the clinical arm of the study.
Briefly, human Tenon's fibroblasts attained from tissue explants from cadaver eyes were
grown until confluent in fetal calf serum containing the standard antibiotics for tissue
culture, gentamicin and amphotericin, and placed in an incubator at 37°C under 95% humidity
with 5% CO2. The cells were passaged when confluent and used for experiments between
passages 3-6.
Alpha smooth muscle actin expression Tenon's fibroblasts were seeded on 24 well plates and
incubated in fetal calf serum (FCS) containing the standard antibiotics for tissue culture,
gentamicin and amphotericin, and placed in an incubator at 37°C under 95% humidity with 5%
CO2. The culture medium was removed after 24 hours and replaced with fresh medium described
below.
Collagen I production Standard 3-D collagen I gels seeded with fibroblasts for gel
contraction assays were employed to quantify collagen production by fibroblasts treated with
different HA concentrations. Gels treated with TGF beta (a known stimulator for collagen I
synthesis and inducer of alpha smooth muscle actin expression ie myofibroblast phenotype)
acted as positive control. Type I collagen derived from rat tail were mixed with culture
medium and following confluency, trypsinised cells were resuspended in this mixture and cast
in a 24 well plate and allowed to polymerise in an incubator at 37°C. After polymerisation,
the gels were gently detached from the plates in which they are cast and suspended in fresh
medium described below
All experiments were conducted in triplicate and repeated 3 times.
Human Tenon's fibroblasts were cultured in fresh media containing HA alone, 5-FU/HA (HA
concentrations10, 14, 23 mg/ml) or cultured without HA or 5FU (controls). Fibrosis and
scarring response of the myofibroblasts was assessed through Collagen I and alpha smooth
muscle actin (ASMA) expression which were quantified by Real Time -Polymerase Chain Reaction
(RT-PCR). WST-1 assay determined cell viability. 5-FU solution or powder was dispersed in HA
and mechanically stirred and then vortex mixed.
Our results showed that HA markedly reduced ASMA and collagen I mRNA expression by
myofibroblasts compared to controls without HA. Treatment with HA following 5FU (10mg/ml)
pretreatment resulted in a greater reduction in ASMA and collagen I expression compared to
HA treatment alone, and statistical significance reached with 23mg/ml HA (p<0.05). Cell
proliferation and viability was not affected by HA.
Our team of investigators has completed the experiments examining the release of 5FU from
the 5FU/ HA mixture. 5FU solution or powder was mechanically stirred and vortex mixed in HA
and the release of 5FU was quantified using high performance liquid chromatography (HPLC).
The concentration of 5FU used was 10mg/ml and the concentration of HA used was 10, 14 and 23
mg/ml.
The 5FU/HA mixture delayed drug release to 48 hours, with HA of 14mg/ml and 23mg/ml showing
a greater delay in drug release than 10mg/ml, (p<0.05). There was no significant difference
in rate of drug release between powder and solution form of 5FU although the pH was notably
different ie 6.6 and 10 respectively.
The results of our in-vitro studies and drug release assays demonstrate that this 5FU/HA
mixture has the desired therapeutic effect on Human Tenon's myofibroblasts. The optimum
concentration for HA is 23mg/ml and it would be combined with 5FU 10mg/ml. We expect that
5FU would be released from the mixture over 48 hours; both HA and 5FU will have
anti-scarring effects in the subconjunctival space.
Patient Recruitment:
Patients will be recruited and randomized at the first postoperative visit where a 5-FU
injection is indicated according to clinical parameters indicating active scar formation.
(usually after the first post-operative month when suturelysis has been completed). All post
operative care apart from the 5FU/viscoelastic mixture injection in the control group will
be unchanged from current treatment standards.
At least 50 patients who have under gone trabeculectomy at the Singapore National Eye Centre
will be recruited in the study from glaucoma clinics at Singapore National Eye Centre. This
will consist of different types of glaucoma. 25 patients will receive subconjunctival
injection of 5FU after bleb needling while 25 will receive injections of a 5FU/ viscoelastic
formulation.
Patient assessment and examination at baseline
All patients (cases and controls) will have the following examination: Snellen visual
acuity, slit-lamp examination of the anterior segment, bleb and intraocular pressure
measurement with a Goldmann tonometer. Tonometry will also be performed pre injection using
a pneumatonometer (Reichert) according to manufacturer's guidelines.
Colour photographs of the bleb will be captured and stored digitally for masked bleb
grading. The Visante OCT will be used to image the bleb morphology in dark conditions. It is
a new non-contact instrument that rapidly obtains high-resolution images of the angle. The
image capture scan takes less than 10 seconds and is akin to taking a photograph. The device
allows qualitative and quantitative angle imaging, which is objective and reproducible. This
will take place prior to the needling procedure.
Bleb needling & subconjunctival injection
Having taken informed consent from the patient, the patient will be assigned into either the
case or control group. In brief, needling of the conjunctival bleb will be carried out at
the slit lamp using an aseptic technique. The doctor performing the procedure will use
sterile gloves and clean the patient's eyelids and peri-orbital skin with povidone iodine
10%. The eye will be anaesthetised with Guttae Tetracaine 0.5% and a wire speculum inserted
to separate the eyelids. Povidone iodine is the inserted into the conjunctival sac. 0.1ml of
lignocaine 2% is injected into the subconjunctival space, temporal or nasal to the bleb
before needling of the bleb is performed with a 27 guage needle attached to a 1ml syringe.
5FU solution (10mg/ml) (control arm) or 5FU/viscoelastic formulation (10mg/ml of 5FU in
23mg/ml HA, (50/50) volume/volume) (experimental arm) is injected posterior to the bleb
after needling is complete. Injections are given within the same quadrant as the bleb. Post
injection the conjunctival sac is thoroughly rinsed and re-examined on the slit-lamp. The
IOP is checked at the end of the procedure using the Goldmann tonometer and the
pneumotonometer.
Patients will receive current standard of care with respect to intraoperative antifibrosis
therapy and the timing and frequency of postoperative 5-FU. Further administration of
subconjunctival 5-FU solution or 5FU/HA formulation, (depending on the treatment arm the
patient was initially assigned to) at subsequent office visits will be administered when
required according to current clinical practice for patients in both treatment arms. This
will be recorded in the study.
Follow-up examinations
Bleb imaging with the Visante anterior segment OCT and IOP measurements will be recorded at
every visit ie week 1, and 12. The need for further needling or other intervention eg
massage/suture removal/lysis (if relevant) will be clinically decided by the ophthalmologist
at each visit and bleb imaging will be performed before any additional procedures perfomed
if it falls on a research visit ie week 1 or 12. Bleb grading from slit lamp photographs
will be performed at baseline pre-injection and at week 12.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A |